Search Follow us


Zubsolv sales of SEK417m were up 83% on FY14, against overall 7.8% market growth. As expected, its 6.4% market share at end FY15 was eroded in January due to the loss of favourable reimbursement status at CVS Caremark. Nevertheless, a 5% price rise, effective February, coupled with a targeted sales effort and stronger marketing message, should help drive sales, particularly as Zubsolv’s reimbursement position improves. With changes in federal legislation on the cusp of significantly increasing the available market, expanding use of medical-assisted treatment and increasing the number of prescribers, Zubsolv remains well positioned. Global expansion with a potential new partner represents further upside.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs